Re­call re­port: Chil­dren's au­to-im­mune dis­ease drug con­t­a­m­i­nat­ed with mold and yeast

A drug used to treat an au­to-im­mune dis­ease in chil­dren has been vol­un­tar­i­ly re­called by drug­mak­er Ja­cobus Phar­ma­ceu­ti­cal af­ter re­ports of the tablets be­ing con­t­a­m­i­nat­ed with yeast, mold and aer­o­bic bac­te­ria.

Three lots of Ruzur­gi 10 mg tablets, used to treat Lam­bert-Eaton myas­thenic syn­drome, have been re­called. The use of the drug in­creas­es the risk of se­ri­ous in­fec­tion, the FDA said.

Two of the three lots of ex­pi­ra­tion dates of March 2023, while a third has an ex­pi­ra­tion date of May 2023.  The lots have con­trol num­bers 18038, 18039 and 18079.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER